Two Years’ Experience of Intensive Home Hemodialysis with the Physidia S3 System: Results from the RECAP Study
Journal of Clinical Medicine · 08.02.2023 · 12 (4) · 1357
DOI: 10.3390/jcm12041357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.02.2023. Verfasst von Hafedh Fessi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Tenon Hospital, 75020 Paris, France. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The RECAP study reports results and outcomes (clinical performances, patient acceptance, cardiac outcomes, and technical survival) achieved with the S3 system used as an intensive home hemodialysis (HHD) platform over a three-year French multicenter study. Ninety-four dialysis patients issued from ten dialysis centers and treated more than 6 months (mean follow-up: 24 months) with S3 were included. A two-hour treatment time was maintained in 2/3 of patients to deliver 25 L of dialysis fluid, while 1/3 required up to 3 h to achieve 30 L. The additional convection volume produced by means of the SeCoHD tool (internal filtration backfiltration) was 3 L/session, and the net ultrafiltration produced to achieve dry weight was 1.4 L/session. On a weekly basis, an average 156 L of dialysate corresponding to 94 L of urea clearance when considering 85% dialysate saturation under low flow conditions was delivered. Such urea clearance was equivalent to 9.2 [8.0–13.0] mL/min weekly urea clearance and a standardized Kt/V of 2.5 [1.1–4.5]. The predialysis concentration of selected uremic markers remained remarkably stable over time. Fluid volume status and blood pressure were adequately controlled by means of a relatively low ultrafiltration rate (7.9 mL/h/kg). Technical survival on S3 was 72% and 58% at 1 and 2 years, respectively. The S3 system was easily handled and kept by patients at home, as indicated by technical survival. Patient perception was improved, while treatment burden was reduced. Cardiac features (assessed in a subset of patients) tended to improve over time. Intensive hemodialysis relying on the S3 system offers a very appealing option for home treatment with quite satisfactory results, as shown in the RECAP study throughout a two-year follow-up time, and offers the best bridging solution to kidney transplantation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, Tenon Hospital, 75020 Paris, France.
- Dialysis Department, Aural Dialysis Center, 69008 Lyon, France.
- Emergency Department, Léman Hospital, 74200 Thonon Les Bains, France.
- Manhès Hospital Center, 91700 Fleury-Mérogis, France.
- Charles Mion Foundation, AIDER-Santé, 34090 Montpellier, France.
- Nephrology Department, University Hospital Center of Besancon, 25000 Besancon, France.
ORCID-Profile: Marion Morena, Bernard Canaud, Jean-Paul Cristol
Zitieren
APA
Fessi, H., Nicoud, P., Serrato, T., Gilbert, O., Courivaud, C., Daoud, S., Morena, M., Thomas, M., Canaud, B., & Cristol, J. P. (2023). Two Years’ Experience of Intensive Home Hemodialysis with the Physidia S3 System: Results from the RECAP Study. Journal of Clinical Medicine, 12(4), 1357. https://doi.org/10.3390/jcm12041357
Vancouver
Fessi H, Nicoud P, Serrato T, Gilbert O, Courivaud C, Daoud S, et al. Two Years’ Experience of Intensive Home Hemodialysis with the Physidia S3 System: Results from the RECAP Study. Journal of Clinical Medicine. 2023;12(4):1357. doi:10.3390/jcm12041357
BibTeX
@article{Fessi2023,
author = {Fessi, Hafedh and Nicoud, Philippe and Serrato, Tomas and Gilbert, Olivia and Courivaud, Cécile and Daoud, Salima and Morena, Marion and Thomas, Michel and Canaud, Bernard and Cristol, Jean-Paul},
title = {Two Years’ Experience of Intensive Home Hemodialysis with the Physidia S3 System: Results from the RECAP Study},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {1357},
doi = {10.3390/jcm12041357}
}
EUVIMED